Advicenne: Half-year results in 2025 and outlook

Advicenne announced a significant increase in its half-year results to June 30, 2025. Total revenue increased by 13% to €2.78 million, driven by an 18% increase in Sibnayal® sales. Revenue increased by 22% to €3.26 million. However, the company recorded a net loss of €4.96 million. This figure was impacted by costs related to preparing the US filing and non-recurring expenses. The cash position stood at €0.52 million, but a debt restructuring and a capital increase extended financial visibility to the end of 2026.

Advicenne expects to file the MA for Sibnayal® in the United States in the fourth quarter of 2025. Its business development strategy in the European and Middle Eastern markets shows a marked increase, with Sibnayal® sales of €5.52 million, an increase of 103%. The company continues to focus on the growth of its flagship product while preparing the groundwork for the launch of ADV7103 across the Atlantic.